Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • AppSealing embraces securing Indian Banks and Fintech’s in the ‘less-cash economy’ Business
  • Lifespan Pvt Ltd becomes the Nodal Testing Agency of Ayush for testing the Identity, Quality & Strength of Ayurvedic, Siddha & Unani Drugs & Raw Materials Business
  • Cambridge, UK based o2h group hosts collaborative innovation conference in Ahmedabad Business
  • Digital Marketing is soon to be all about AI says Shabbir Hussain – Co-Founder at Hats-Off Digital Pvt. Ltd Business
  • Maharashtra Housing Corporation’s Villament Township Set to Revolutionize Pune Real Estate Business
  • Azura Media Event Pvt Ltd, An Ideal Event Management Company English
  • Richa Info Systems set to open its IPO on 9th February 2022 Business
  • Heart-IN-Heart: Rising to Top in Life, Passion, Romance Business

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

Posted on April 29, 2021 By dsprime 22 Comments on ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

ISSAR Pharma, the only company in India which focuses on the research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

Hyderabad (Telangana) [India], April 29: ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides, and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

“We take pride in being India’s first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, the founder of ISSAR. ISSAR’s

FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and a prime focus in Research and Development, ISSAR’s dedicated team of experts is proud to have developed India’s first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Mr. Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients’ quality of life. Before starting ISSAR Pharmaceutical, Mr.Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when Biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with 2 successfully commercialized products, 7 plus patents to his credit, and over 6 commercially viable products under development.

https://issar.co.in/

English, Health, Press Release Tags:ISSARPharma, PeptidebasedNCEs, PNN

Post navigation

Previous Post: Glimpse up the world @worldwithmaria
Next Post: Indian Furniture Rental Industry – Market Size, Growth & Scope

Related Posts

  • BA Pass 3 to launch on Filmybox app on May 1st, 2021 English
  • Ahmedabad to host Rakshak – Ek Shaam Gujarat Police Ke Naam to salute efforts of police personnel Press Release
  • India’s First Most Trustable Multiple Bank Loan Offer Membership Card Provider Company – Nowofloan.Com Press Release
  • “Navigator Emerging Market Fund’’ is all set to become a market leader by Building and Preserving Wealth Business
  • Entrepreneur “Ansh Handa” achieves new heights of success in Digital Business A
  • Entrepreneur Sanjay Nigam announces second season of India Fashion Awards English

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Maharashtra Class Owners’ Association (MCOA) Teacher’s Day Celebration was a mix of Awards, Recognition, Networking and Performances
  • Utkarsh Small Finance Bank Leads the Way with Interoperable Cardless Cash Withdrawal (ICCW) Using UPI on ATMs
  • Team Marksmen Network’s CX Transformation Conclave highlights the business case and criticality of great CX
  • Star Gold to Present The World TV Premiere of IB71, a Gripping Tale of India’s 1971 Airlines Hijacking on 23rd September at 8 pm!
  • Sanjay Mishra’s “Dvand – THE INTERNAL CONFLICT” Unveils Gripping Trailer releasing on 29th September 2023 

Recent Comments

    • Dr. Rakesh Tawar, Leading Plastic Surgeon in Dehradun, Shares Insights on the Latest Advancements in Cosmetic Surgery Business
    • ‘MSME Banking Conclave & Expo 2022’ aims to craft a financial roadmap for the Indian MSMEs Business
    • Billionaire Philanthropist Sudha Reddy To Represent India at Paris Haute Couture Week Business
    • Continuing the Noble Mission Lifestyle
    • Leading Lady Detective Savvy Sonawane Brings Justice to Those in Need Through Expert Investigation Services Business
    • Cloudphysician’s Smart-ICU Solution provides access to India’s best intensivists to hospitals across India using technology Health
    • Crown Group Defence Highlights the Importance of Home-Grown MRO Capabilities for the Indian Defence Sector Business
    • Bollywood Star Suniel Shetty Joins Celebration as Anniversary Couple Navneet & Neena Kapoor Mark 25 Years of Love and Commitment – World News Network Business

    Copyright © 2023 Daily News India.

    Powered by PressBook News WordPress theme